Cholinesterase Inhibitors in the Management of Canine Cognitive Dysfunction: A Review on the Mechanisms of Action, Current Evidence from Experimental and Clinical Studies, and Future Directions
Animals · 20.11.2026 · 16 (22) · 3692
DOI: 10.3390/ani16223692 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animals, online erschienen am 20.11.2026. Verfasst von Tomaž Trobec. Die Arbeit nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Slovenian Research and Innovation Agency.
Abstract (Originalsprache)
Canine cognitive dysfunction is a progressive, age-related neurodegenerative disorder that shares several clinical and neuropathological features with human Alzheimer’s disease, although important differences exist between the two conditions. The central mechanisms underlying the pathophysiology of canine cognitive dysfunction include the accumulation of amyloid-β plaques, cytoplasmic deposits of phosphorylated tau protein with rarely observed neurofibrillary tangles, cortical brain atrophy, and disturbances in neurotransmitters, particularly within cholinergic pathways. Compared with those in age-matched, cognitively unimpaired and young cohorts, the number of cholinergic neurons in the basal forebrain in old, cognitively impaired dogs is significantly lower. However, cholinergic deficit does not correlate directly with cortical amyloid-β load. These neurochemical and structural changes contribute to the characteristic cognitive and behavioral deficits of canine cognitive dysfunction. Cholinesterase inhibitors, which increase synaptic acetylcholine levels by inhibiting acetylcholinesterase and/or butyrylcholinesterase, have emerged as a promising pharmacological strategy. This review critically evaluates current evidence from experimental studies investigating the effects of cholinesterase inhibitors on age-associated cognitive performance in laboratory beagle dogs, as well as clinical studies involving client-owned dogs diagnosed with canine cognitive dysfunction; describes their mechanistic basis; and outlines currently available symptomatic pharmacological interventions, such as the monoamine oxidase B inhibitor selegiline (L-deprenyl), and non-pharmacological interventions, including environmental enrichment, regular exercise, diet, and nutritional supplements. Furthermore, it identifies knowledge gaps and proposes future research directions that could support the translation of cholinesterase inhibitors into effective therapeutic interventions for improving cognitive function and quality of life in aging dog populations.
Förderung
- The Slovenian Research and Innovation Agency
Zitieren
APA
Trobec, T. (2026). Cholinesterase Inhibitors in the Management of Canine Cognitive Dysfunction: A Review on the Mechanisms of Action, Current Evidence from Experimental and Clinical Studies, and Future Directions. Animals, 16(22), 3692. https://doi.org/10.3390/ani16223692
Vancouver
Trobec T. Cholinesterase Inhibitors in the Management of Canine Cognitive Dysfunction: A Review on the Mechanisms of Action, Current Evidence from Experimental and Clinical Studies, and Future Directions. Animals. 2026;16(22):3692. doi:10.3390/ani16223692
BibTeX
@article{Trobec2026,
author = {Trobec, Tomaž},
title = {Cholinesterase Inhibitors in the Management of Canine Cognitive Dysfunction: A Review on the Mechanisms of Action, Current Evidence from Experimental and Clinical Studies, and Future Directions},
journal = {Animals},
year = {2026},
volume = {16},
number = {22},
pages = {3692},
doi = {10.3390/ani16223692}
}
EUVIMED